Top

Published in:

Open Access 01-12-2020 | Magnetic Resonance Imaging | Study protocol

The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson’s disease

Authors: A. F. Wolters, M. Heijmans, S. Michielse, A. F. G. Leentjens, A. A. Postma, J. F. A. Jansen, D. Ivanov, A. A. Duits, Y. Temel, M. L. Kuijf

Published in: BMC Neurology | Issue 1/2020

Abstract

Background

The diagnosis of Parkinson’s Disease (PD) remains a challenge and is currently based on the assessment of clinical symptoms. PD is also a heterogeneous disease with great variability in symptoms, disease course, and response to therapy. There is a general need for a better understanding of this heterogeneity and the interlinked long-term changes in brain function and structure in PD. Over the past years there is increasing interest in the value of new paradigms in Magnetic Resonance Imaging (MRI) and the potential of ultra-high field strength imaging in the diagnostic work-up of PD. With this multimodal 7 T MRI study, our objectives are: 1) To identify distinctive MRI characteristics in PD patients and to create a diagnostic tool based on these differences. 2) To correlate MRI characteristics to clinical phenotype, genetics and progression of symptoms. 3) To detect future imaging biomarkers for disease progression that could be valuable for the evaluation of new therapies.

Methods

The TRACK-PD study is a longitudinal observational study in a cohort of 130 recently diagnosed (≤ 3 years after diagnosis) PD patients and 60 age-matched healthy controls (HC). A 7 T MRI of the brain will be performed at baseline and repeated after 2 and 4 years. Complete assessment of motor, cognitive, neuropsychiatric and autonomic symptoms will be performed at baseline and follow-up visits with wearable sensors, validated questionnaires and rating scales. At baseline a blood DNA sample will also be collected.

Discussion

This is the first longitudinal, observational, 7 T MRI study in PD patients. With this study, an important contribution can be made to the improvement of the current diagnostic process in PD. Moreover, this study will be able to provide valuable information related to the different clinical phenotypes of PD and their correlating MRI characteristics. The long-term aim of this study is to better understand PD and develop new biomarkers for disease progression which may help new therapy development. Eventually, this may lead to predictive models for individual PD patients and towards personalized medicine in the future.

Trial registration

Dutch Trial Register, NL7558. Registered March 11, 2019.

Jankovic J. Parkinson's disease: clinical features and diagnosis. J Neurol Neurosurg Psychiatry. 2008;79(4):368–76.PubMed

Al-Radaideh AM, Rababah EM. The role of magnetic resonance imaging in the diagnosis of Parkinson's disease: a review. Clin Imaging. 2016;40(5):987–96.PubMed

Postuma RB, Berg D, Stern M, Poewe W, Olanow CW, Oertel W, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015;30(12):1591–601.PubMed

Hughes AJ, Daniel SE, Ben-Shlomo Y, Lees AJ. The accuracy of diagnosis of parkinsonian syndromes in a specialist movement disorder service. Brain. 2002;125(Pt 4):861–70.PubMed

Konno T, Deutschlander A, Heckman MG, Ossi M, Vargas ER, Strongosky AJ, et al. Comparison of clinical features among Parkinson's disease subtypes: a large retrospective study in a single center. J Neurol Sci. 2018;386:39–45.PubMed

Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB. Clinical criteria for subtyping Parkinson's disease: biomarkers and longitudinal progression. Brain. 2017;140(7):1959–76.PubMed

Iwaki H, Blauwendraat C, Leonard HL, Liu G, Maple-Grodem J, Corvol JC, et al. Genetic risk of Parkinson disease and progression: An analysis of 13 longitudinal cohorts. Neurol Genet 2019;5(4):e348.

Thenganatt MA, Jankovic J. Parkinson disease subtypes. JAMA Neurol. 2014;71(4):499–504.PubMed

Sieber BA, Landis S, Koroshetz W, Bateman R, Siderowf A, Galpern WR, et al. Prioritized research recommendations from the National Institute of Neurological Disorders and Stroke Parkinson's disease 2014 conference. Ann Neurol. 2014;76(4):469–72.PubMedPubMedCentral

10.

Lehericy S, Vaillancourt DE, Seppi K, Monchi O, Rektorova I, Antonini A, et al. The role of high-field magnetic resonance imaging in parkinsonian disorders: pushing the boundaries forward. Mov Disord. 2017;32(4):510–25.PubMed

11.

Schwarz ST, Afzal M, Morgan PS, Bajaj N, Gowland PA, Auer DP. The 'swallow tail' appearance of the healthy nigrosome - a new accurate test of Parkinson's disease: a case-control and retrospective cross-sectional MRI study at 3T. PLoS One. 2014;9(4):e93814.PubMedPubMedCentral

12.

Reiter E, Mueller C, Pinter B, Krismer F, Scherfler C, Esterhammer R, et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative parkinsonism. Mov Disord. 2015;30(8):1068–76.PubMed

13.

Bae YJ, Kim JM, Kim E, Lee KM, Kang SY, Park HS, et al. Loss of Nigral Hyperintensity on 3 tesla MRI of parkinsonism: comparison with (123) I-FP-CIT SPECT. Mov Disord. 2016;31(5):684–92.PubMed

14.

Castellanos G, Fernandez-Seara MA, Lorenzo-Betancor O, Ortega-Cubero S, Puigvert M, Uranga J, et al. Automated neuromelanin imaging as a diagnostic biomarker for Parkinson's disease. Mov Disord. 2015;30(7):945–52.PubMed

15.

Wolters AF, van de Weijer SCF, Leentjens AFG, Duits AA, Jacobs HIL, Kuijf ML. Resting-state fMRI in Parkinson's disease patients with cognitive impairment: a meta-analysis. Parkinsonism Relat Disord. 2019;62:16–27.PubMed

16.

Filippi M, Elisabetta S, Piramide N, Agosta F. Functional MRI in idiopathic Parkinson's disease. Int Rev Neurobiol. 2018;141:439–67.PubMed

17.

Association AP. Diagnostic and statistical manual of mental disorders (DSM-5®): American psychiatric pub; 2013.

18.

Tomlinson CL, Stowe R, Patel S, Rick C, Gray R, Clarke CE. Systematic review of levodopa dose equivalency reporting in Parkinson's disease. Mov Disord. 2010;25(15):2649–53.PubMed

19.

Bloem BR, Marks WJ Jr, Silva de Lima AL, Kuijf ML, van Laar T, BPF J, et al. The Personalized Parkinson Project: examining disease progression through broad biomarkers in early Parkinson's disease. BMC Neurol. 2019;19(1):160.PubMedPubMedCentral

20.

Manniën J, Ledderhof T, Verspaget HW, Snijder RR, Flikkenschild EF, van Scherrenburg NPC, Stolk RP, Zielhuis GA. The Parelsnoer institute: a National Network of standardized clinical biobanks in the Netherlands. Open J Bioresources. 2017;4(1):3.

21.

Goetz CG, Poewe W, Rascol O, Sampaio C, Stebbins GT, Counsell C, et al. Movement disorder society task force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19(9):1020–8.PubMed

22.

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, et al. Movement Disorder Society-sponsored revision of the unified Parkinson's disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129–70.

23.

Heijmans M, Habets JGV, Herff C, Aarts J, Stevens A, Kuijf ML, et al. Monitoring Parkinson's disease symptoms during daily life: a feasibility study. NPJ Parkinsons Dis. 2019;5:21.PubMedPubMedCentral

24.

Visser M, Marinus J, Stiggelbout AM, Van Hilten JJ. Assessment of autonomic dysfunction in Parkinson's disease: the SCOPA-AUT. Mov Disord. 2004;19(11):1306–12.PubMed

25.

Palavra NC, Naismith SL, Lewis SJ. Mild cognitive impairment in Parkinson's disease: a review of current concepts. Neurol Res Int. 2013;2013:576091.PubMedPubMedCentral

26.

Gladsjo JA, Schuman CC, Evans JD, Peavy GM, Miller SW, Heaton RK. Norms for letter and category fluency: demographic corrections for age, education, and ethnicity. Assessment. 1999;6(2):147–78.PubMed

27.

Vakil E, Blachstein H. Rey auditory-verbal learning test: structure analysis. J Clin Psychol. 1993;49(6):883–90.PubMed

28.

Benton AL, Varney NR, Hamsher KD. Visuospatial judgment. A clinical test. Arch Neurol. 1978;35(6):364–7.PubMed

29.

Smith A. Symbol digit modalities test (SDMT) manual. Los Angeles: Western Psychological Services; 1982.

30.

Wechsler D. Wechsler adult intelligence scale. San Antonio: Psychological Corporation; 2008.

31.

Visser M, Leentjens AF, Marinus J, Stiggelbout AM, van Hilten JJ. Reliability and validity of the Beck depression inventory in patients with Parkinson's disease. Mov Disord. 2006;21(5):668–72.PubMed

32.

Leentjens AF, Dujardin K, Pontone GM, Starkstein SE, Weintraub D, Martinez-Martin P. The Parkinson anxiety scale (PAS): development and validation of a new anxiety scale. Mov Disord. 2014;29(8):1035–43.PubMed

33.

Probst CC, Winter LM, Moller B, Weber H, Weintraub D, Witt K, et al. Validation of the questionnaire for impulsive-compulsive disorders in Parkinson's disease (QUIP) and the QUIP-rating scale in a German speaking sample. J Neurol. 2014;261(5):936–42.PubMedPubMedCentral

34.

Luo N, Tan LC, Zhao Y, Lau PN, Au WL, Li SC. Determination of the longitudinal validity and minimally important difference of the 8-item Parkinson's disease questionnaire (PDQ-8). Mov Disord. 2009;24(2):183–7.PubMed

35.

Stiasny-Kolster K, Mayer G, Schafer S, Moller JC, Heinzel-Gutenbrunner M, Oertel WH. The REM sleep behavior disorder screening questionnaire--a new diagnostic instrument. Mov Disord. 2007;22(16):2386–93.PubMed

36.

Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol. 2020;19(2):170–8.PubMed

37.

Jakubowski JL, Labrie V. Epigenetic biomarkers for Parkinson's disease: from diagnostics to therapeutics. J Parkinsons Dis. 2017;7(1):1–12.PubMedPubMedCentral

38.

Teeuwisse WM, Brink WM, Webb AG. Quantitative assessment of the effects of high-permittivity pads in 7 tesla MRI of the brain. Magn Reson Med. 2012;67(5):1285–93.PubMed

39.

Eggenschwiler F, Kober T, Magill AW, Gruetter R, Marques JP. SA2RAGE: a new sequence for fast B1+ −mapping. Magn Reson Med. 2012;67(6):1609–19.PubMed

40.

Priovoulos N, Jacobs HIL, Ivanov D, Uludag K, Verhey FRJ, Poser BA. High-resolution in vivo imaging of human locus coeruleus by magnetization transfer MRI at 3T and 7T. Neuroimage. 2018;168:427–36.PubMed

41.

Wieler M, Gee M, Martin WR. Longitudinal midbrain changes in early Parkinson's disease: iron content estimated from R2*/MRI. Parkinsonism Relat Disord. 2015;21(3):179–83.PubMed

42.

Ofori E, Pasternak O, Planetta PJ, Li H, Burciu RG, Snyder AF, et al. Longitudinal changes in free-water within the substantia nigra of Parkinson's disease. Brain. 2015;138(Pt 8):2322–31.PubMedPubMedCentral

43.

Ulla M, Bonny JM, Ouchchane L, Rieu I, Claise B, Durif F. Is R2* a new MRI biomarker for the progression of Parkinson's disease? A longitudinal follow-up. PLoS One. 2013;8(3):e57904.PubMedPubMedCentral

44.

Mak E, Su L, Williams GB, Firbank MJ, Lawson RA, Yarnall AJ, et al. Baseline and longitudinal grey matter changes in newly diagnosed Parkinson's disease: ICICLE-PD study. Brain. 2015;138(Pt 10):2974–86.PubMedPubMedCentral

45.

Alkemade A, de Hollander G, Keuken MC, Schafer A, Ott DVM, Schwarz J, et al. Comparison of T2*-weighted and QSM contrasts in Parkinson's disease to visualize the STN with MRI. PLoS One. 2017;12(4):e0176130.PubMedPubMedCentral

46.

Kim JM, Jeong HJ, Bae YJ, Park SY, Kim E, Kang SY, et al. Loss of substantia nigra hyperintensity on 7 tesla MRI of Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy. Parkinsonism Relat Disord. 2016;26:47–54.PubMed

47.

Pyatigorskaya N, Magnin B, Mongin M, Yahia-Cherif L, Valabregue R, Arnaldi D, et al. Comparative study of MRI biomarkers in the Substantia Nigra to discriminate idiopathic Parkinson disease. AJNR Am J Neuroradiol. 2018;39(8):1460–7.PubMed

48.

Cosottini M, Frosini D, Pesaresi I, Costagli M, Biagi L, Ceravolo R, et al. MR imaging of the substantia nigra at 7 T enables diagnosis of Parkinson disease. Radiology. 2014;271(3):831–8.PubMed

49.

Schmidt MA, Engelhorn T, Marxreiter F, Winkler J, Lang S, Kloska S, et al. Ultra high-field SWI of the substantia nigra at 7T: reliability and consistency of the swallow-tail sign. BMC Neurol. 2017;17(1):194.PubMedPubMedCentral

50.

Faul F, Erdfelder E, Lang AG, Buchner A. G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences. Behav Res Methods. 2007;39(2):175–91.

51.

Gorgolewski KJ, Alfaro-Almagro F, Auer T, Bellec P, Capota M, Chakravarty MM, et al. BIDS apps: improving ease of use, accessibility, and reproducibility of neuroimaging data analysis methods. PLoS Comput Biol. 2017;13(3):e1005209.PubMedPubMedCentral

52.

Li X, Morgan PS, Ashburner J, Smith J, Rorden C. The first step for neuroimaging data analysis: DICOM to NIfTI conversion. J Neurosci Methods. 2016;264:47–56.PubMed

53.

Jenkinson M, Beckmann CF, Behrens TE, Woolrich MW, Smith SM. Fsl. Neuroimage. 2012;62(2):782–90.

54.

Dale AM, Fischl B, Sereno MI. Cortical surface-based analysis. I. Segmentation and surface reconstruction. Neuroimage. 1999;9(2):179–94.PubMed

55.

Cole DM, Beckmann CF, Oei NY, Both S, van Gerven JM, Rombouts SA. Differential and distributed effects of dopamine neuromodulations on resting-state network connectivity. Neuroimage. 2013;78:59–67.PubMed

56.

Dang LC, O'Neil JP, Jagust WJ. Dopamine supports coupling of attention-related networks. J Neurosci. 2012;32(28):9582–7.PubMedPubMedCentral

57.

Hatano T, Okuzumi A, Kamagata K, Daida K, Taniguchi D, Hori M, et al. Neuromelanin MRI is useful for monitoring motor complications in Parkinson's and PARK2 disease. J Neural Transm (Vienna). 2017;124(4):407–15.

58.

Tahmasian M, Eickhoff SB, Giehl K, Schwartz F, Herz DM, Drzezga A, et al. Resting-state functional reorganization in Parkinson's disease: an activation likelihood estimation meta-analysis. Cortex. 2017;92:119–38.PubMed

59.

Parkinson Progression Marker I. The Parkinson Progression Marker initiative (PPMI). Prog Neurobiol. 2011;95(4):629–35.

60.

Sanchez-Ferro A, Elshehabi M, Godinho C, Salkovic D, Hobert MA, Domingos J, et al. New methods for the assessment of Parkinson's disease (2005 to 2015): a systematic review. Mov Disord. 2016;31(9):1283–92.PubMed

61.

Delrobaei M, Memar S, Pieterman M, Stratton TW, McIsaac K, Jog M. Towards remote monitoring of Parkinson's disease tremor using wearable motion capture systems. J Neurol Sci. 2018;384:38–45.PubMed

62.

Rodriguez-Martin D, Sama A, Perez-Lopez C, Catala A, Moreno Arostegui JM, Cabestany J, et al. Home detection of freezing of gait using support vector machines through a single waist-worn triaxial accelerometer. PLoS One. 2017;12(2):e0171764.PubMedPubMedCentral

63.

Griffiths RI, Kotschet K, Arfon S, Xu ZM, Johnson W, Drago J, et al. Automated assessment of bradykinesia and dyskinesia in Parkinson's disease. J Parkinsons Dis. 2012;2(1):47–55.PubMed

64.

Delrobaei M, Baktash N, Gilmore G, McIsaac K, Jog M. Using wearable technology to generate objective Parkinson's disease dyskinesia severity score: possibilities for home monitoring. IEEE Trans Neural Syst Rehabil Eng. 2017;25(10):1853–63.PubMed

65.

Plantinga BR, Temel Y, Duchin Y, Uludag K, Patriat R, Roebroeck A, et al. Individualized parcellation of the subthalamic nucleus in patients with Parkinson's disease with 7T MRI. Neuroimage. 2018;168:403–11.PubMed

Title: The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson’s disease
Authors: A. F. Wolters
M. Heijmans
S. Michielse
A. F. G. Leentjens
A. A. Postma
J. F. A. Jansen
D. Ivanov
A. A. Duits
Y. Temel
M. L. Kuijf
Publication date: 01-12-2020
Publisher: BioMed Central
Keywords: Magnetic Resonance Imaging
Magnetic Resonance Imaging
Parkinson's Disease
Biomarkers
Published in: BMC Neurology / Issue 1/2020
Electronic ISSN: 1471-2377
DOI: https://doi.org/10.1186/s12883-020-01874-2

Keynote webinar | Spotlight on medication adherence

Springer Medicine

The TRACK-PD study: protocol of a longitudinal ultra-high field imaging study in Parkinson’s disease

Abstract

Background

Methods

Discussion

Trial registration

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Discussion

Trial registration

Please log in to get access to this content

Other articles of this Issue 1/2020

Normal pressure hydrocephalus secondary to Lyme disease, a case report and review of seven reported cases

Practical value of three-dimensional high resolution magnetic resonance Vessel Wall imaging in identifying suspicious intracranial vertebrobasilar dissecting aneurysms

Induced neuroprotection by remote ischemic perconditioning as a new paradigm in ischemic stroke at the acute phase, a systematic review

Comparison of cervical disc arthroplasty and anterior cervical discectomy and fusion for the treatment of cervical disc degenerative diseases on the basis of more than 60 months of follow-up: a systematic review and meta-analysis

Percutaneous mastoid electrical stimulator improves Poststroke depression and cognitive function in patients with Ischaemic stroke: a prospective, randomized, double-blind, and sham-controlled study

Cervical artery dissection—an easily neglected cause of stroke: a case report